

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJMN1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	10	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	11	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	12	JUN 25	CA/CAPplus and USPAT databases updated with IPC reclassification data
NEWS	13	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	14	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	15	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	16	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	17	JUL 28	CA/CAPplus patent coverage enhanced
NEWS	18	JUL 28	EPFULL enhanced with additional legal status information from the epline Register
NEWS	19	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	20	JUL 28	STN Viewer performance improved
NEWS	21	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	22	AUG 13	CA/CAPplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	23	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	24	AUG 15	CAPplus currency for Korean patents enhanced
NEWS	25	AUG 25	CA/CAPplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS	26	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information

NEWS 27 SEP 18 Support for STN Express, Versions 6.01 and earlier,
to be discontinued

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:15:55 ON 19 SEP 2008

=> FIL REG		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:16:06 ON 19 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 SEP 2008 HIGHEST RN 1049989-16-3
DICTIONARY FILE UPDATES: 17 SEP 2008 HIGHEST RN 1049989-16-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10581340\1.str



chain nodes :
 1 2 3 4 5 6 7 8 14 18
 ring nodes :
 9 10 11 12 13
 chain bonds :
 1-2 2-3 2-5 3-4 3-6 7-8 13-14
 ring bonds :
 9-10 9-13 10-11 11-12 12-13
 exact/norm bonds :
 2-5 3-4 3-6 7-8 9-10 9-13 10-11 11-12 12-13 13-14
 exact bonds :
 1-2 2-3

G1:NO2, [*1], [*2]

Match level :
 1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:Atom
 10:Atom 11:Atom 12:Atom 13:Atom 14:CLASS 18:CLASS



L1 STRUCTURE UPLOADED

=> D

~~L1 HAS NO ANSWERS~~

L1 STR

G1



G1 NO2, [01],[02]

Structure attributes must be viewed using STN Express query preparation.

=> S L1

SAMPLE SEARCH INITIATED 14:16:24 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5619 TO ITERATE

35.6% PROCESSED 2000 ITERATIONS

31 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**


PROJECTED ITERATIONS: 107885 TO 116875

PROJECTED ANSWERS: 1182 TO 2300

L2 31 SEA SSS SAM L1

=> D SCAN

L2 31 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Pyridinepropanoic acid, 2-methyl-5-nitro- α -oxo-, ethyl ester
 MF C11 H12 N2 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 31 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Glycinamide, N-[[5-(4-chlorophenyl)-2-furanyl]carbonyl]-L-isoleucyl-3-cyclohexyl-L-alanyl-(3S)-3-amino-2-oxopentanoyl-N-[(3-nitrophenyl)sulfonyl]- (9CI)
 SQL 4
 MF C39 H47 Cl N6 O11 S


RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 31 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L- α -aspartyl-N-[4-[[imino(nitroamino)methyl]amino]-1-oxo[(3-phenylpropyl)amino]acetyl]butyl]-, phenylmethyl ester, (S)- (9CI)
 MF C37 H50 N8 O10


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 31 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Pyruvic acid, [4-(benzylthio)-2-nitrophenyl]- (7CI)
 MF C16 H13 N O5 S







PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\STNEXP\Queries\10581340\2.str



chain nodes :

1 2 3 4 5 6 12

ring nodes :

7 8 9 10 11

chain bonds :

1-2 2-3 2-5 3-4 3-6 11-12

ring bonds :

7-8 7-11 8-9 9-10 10-11

exact/norm bonds :

2-5 3-4 3-6 7-8 7-11 8-9 9-10 10-11 11-12

exact bonds :

1-2 2-3

G1:NO2

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 9:Atom



10:Atom 11:Atom 12:CLASS

L3 STRUCTURE UPLOADED

=> D

L3 HAS NO ANSWERS

L3 STR



G1 NO2

Structure attributes must be viewed using STN Express query preparation.

=> S L3

SAMPLE SEARCH INITIATED 14:17:34 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0

PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> S L3 FULL

FULL SEARCH INITIATED 14:17:40 FILE 'REGISTRY'


FULL SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L5 0 SEA SSS FUL L3

=>

Uploading C:\Program Files\STNEXP\Queries\10581340\3.str



chain nodes :

1 2 3 4 5 11

ring nodes :

6 7 8 9 10

chain bonds :

1-2 2-3 2-4 3-5 10-11

ring bonds :

6-7 6-10 7-8 8-9 9-10

exact/norm bonds :

2-4 3-5 6-7 6-10 7-8 8-9 9-10 10-11

exact bonds :

1-2 2-3


G1:NO2

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:CLASS

L6 STRUCTURE UPLOADED

=> D
L6 HAS NO ANSWERS
L6 STR



G1 NO2

Structure attributes must be viewed using STN Express query preparation.

=> S L6
SAMPLE SEARCH INITIATED 14:18:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0



L7 0 SEA SSS SAM L6

=> S L6 FULL
FULL SEARCH INITIATED 14:18:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L8 0 SEA SSS FUL L6

=>
Uploading C:\Program Files\STNEXP\Queries\10581340\4.str




chain nodes :
 1 2 3 4 5 7 8
 chain bonds :
 1-2 2-3 2-4 3-5 7-8
 exact/norm bonds :
 2-4 3-5 7-8
 exact bonds :
 1-2 2-3

G1:NO2

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 7:CLASS 8:CLASS



G1 NO2

Structure attributes must be viewed using STN Express query preparation.

=> S L9

SAMPLE SEARCH INITIATED 14:22:10 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 217 TO ITERATE

100.0% PROCESSED 217 ITERATIONS
 SEARCH TIME: 00.00.01


4 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3457 TO 5223
PROJECTED ANSWERS: 4 TO 200

L10 4 SEA SSS SAM L9

=> D SCAN


L10 4 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanoic acid, 2-oxo-, 2-(nitrooxy)-1-[(nitrooxy)methyl]ethyl ester
MF C6 H8 N2 O9



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L10 4 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanoic acid, 2-oxo-, 2-nitro-3-(nitrooxy)-2-[(nitrooxy)methyl]propyl ester
MF C7 H9 N3 O11



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> S L9 FULL
FULL SEARCH INITIATED 14:22:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      4141 TO ITERATE

100.0% PROCESSED      4141 ITERATIONS      122 ANSWERS
SEARCH TIME: 00.00.01

L11      122 SEA SSS FUL L9
```

```
=> FIL CAPLUS
COST IN U.S. DOLLARS      SINCE FILE      TOTAL
                           ENTRY      SESSION
FULL ESTIMATED COST      538.76      538.97
```

FILE 'CAPLUS' ENTERED AT 14:22:35 ON 19 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2008 VOL 149 ISS 13
FILE LAST UPDATED: 18 Sep 2008 (20080918/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

```
=> S L11
L12      9 L11

=> D IBIB 1
```

L12 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:339268 CAPLUS
DOCUMENT NUMBER: 148:449109
TITLE: Thermal stability of carbonyl radicals. Part II.
Reactions of methylglyoxyl and methylglyoxylperoxy
radicals at 1 bar in the temperature range 275-311 K
AUTHOR(S): Jagiella, Stefan; Zabel, Friedhelm
CORPORATE SOURCE: Institut fuer Physikalische Chemie, Universitaet
Stuttgart, Stuttgart, D-70569, Germany
SOURCE: Physical Chemistry Chemical Physics (2008), 10(13),
1799-1808
CODEN: PPCPFQ; ISSN: 1463-9076
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR
THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:588522 CAPLUS
 DOCUMENT NUMBER: 143:120530
 TITLE: Nitric oxide-releasing pyruvate compounds,
 compositions and methods for treating cardiovascular
 and other diseases
 INVENTOR(S): Garvey, David S.; Fang, Xinqin; Subhash, Khanapure
 P.;
 PATENT ASSIGNEE(S): Ramani, Ranatunga R.; Shlow-Jyi, Wey
 SOURCE: NitroMed, Inc., USA
 PCT Int. Appl., 82 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060603	A2	20050707	WO 2004-US41069	20041210
WO 2005060603	A3	20051201		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GB, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004305016	A1	20050707	AU 2004-305016	20041210
CA 2549412	A1	20050707	CA 2004-2549412	20041210
EP 1692107	A2	20060823	EP 2004-813393	20041210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
PRIORITY APPLN. INFO.:			US 2003-528184P	F 20031210
			WO 2004-US41069	W 20041210

OTHER SOURCE(S): MARPAT 143:120530

L12 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:432749 CAPLUS
DOCUMENT NUMBER: 143:178225
TITLE: Atmospheric Chemistry of C3-C6
Cycloalkanecarbaldehydes
AUTHOR(S): D'Anna, Barbara; Wisthaler, Armin; Andreassen,
Oeyvind;
Hansel, Armin; Hjorth, Jens; Jensen, Niels R.;
Nielsen, Claus J.; Stenstrom, Yngve; Vildanoja, Jyrki
CORPORATE SOURCE: Department of Chemistry, University of Oslo, Oslo,
N-0315, Norway
SOURCE: Journal of Physical Chemistry A (2005), 109(23),
5104-5118
CODEN: JPCLFH; ISSN: 1089-5639
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR
THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L12 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:804127 CAPLUS
DOCUMENT NUMBER: 141:405654
TITLE: NO-Sartans: A New Class of Pharmacodynamic Hybrids as
Cardiovascular Drugs
AUTHOR(S): Breschi, Maria C.; Calderone, Vincenzo; Digiacomo,
Maria; Martelli, Alma; Martinotti, Enrica; Minutolo,
Filippo; Rapposelli, Simona; Balsamo, Aldo
CORPORATE SOURCE: Dipartimento di Psichiatria, Neurobiologia,
Farmacologia e Biotecnologie, Universita di Pisa,
Pisa, 56126, Italy
SOURCE: Journal of Medicinal Chemistry (2004), 47(23),
5597-5600
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:405654
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


L12 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:432749 CAPLUS
DOCUMENT NUMBER: 143:178225
TITLE: Atmospheric Chemistry of C3-C6
Cycloalkanecarbaldehydes
AUTHOR(S): D'Anna, Barbara; Wisthaler, Armin; Andreasen,
Oeyvind;
Hansel, Armin; Hjorth, Jens; Jensen, Niels R.;
Nielsen, Claus J.; Stenstrom, Yngve; Vildanoja, Jyrki
CORPORATE SOURCE: Department of Chemistry, University of Oslo, Oslo,
N-0315, Norway
SOURCE: Journal of Physical Chemistry A (2005), 109(23),
5104-5118
CODEN: JPCLFH; ISSN: 1089-5639
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR
THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 INVENTION NUMBER: 2005:588522 CAPLUS
 DOCUMENT NUMBER: 143:120530
 TITLE: Nitric oxide-releasing pyruvate compounds, compositions and methods for treating cardiovascular and other diseases
 INVENTOR(S): Garvey, David S.; Fang, Xinqin; Subhash, Khanapure P.;
 PATENT ASSIGNEE(S): Ramani, Ranatunga R.; Shioy-Jyi, Wey
 SOURCE: NitroMed, Inc., USA
 PCT Int. Appl., 82 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM.: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060603	A2	20050707	WO 2004-US41069	20041210
WO 2005060603	A3	20051201		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GB, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004305016	A1	20050707	AU 2004-305016	20041210
CA 2549412	A1	20050707	CA 2004-2549412	20041210
EP 1692107	A2	20060823	EP 2004-813393	20041210
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
PRIORITY APPLN. INFO.:		US 2003-528184P	F	20031210
		WO 2004-US41069	W	20041210

OTHER SOURCE(S): MARPAT 143:120530
 AB The invention describes novel pyruvate compds. comprising at least one nitric oxide-releasing group and pharmaceutically acceptable salts thereof, and compns. and kits comprising at least one of these pyruvate compds., and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The therapeutic agent is, e.g., an aldosterone antagonist, α -adrenoceptor antagonist, an angiotensin II antagonist, an ACE inhibitor, an antidiabetic, an antihyperlipidemic agent, an antioxidant, an antithrombotic, a vasodilator, a β -adrenoceptor antagonist, a calcium channel blocker, a digitalis, a diuretic, etc. The invention also provides methods for treating cardiovascular diseases, renovascular diseases, diabetes, diseases resulting from oxidative stress, endothelial dysfunctions, diseases caused by endothelial dysfunctions,


L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 857465-26-0P 857465-27-1P 857465-28-2P
 857465-29-3P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of nitric oxide-releasing pyruvate compds. and compns. for treating cardiovascular and other diseases)
 RN 857464-11-0 CAPLUS
 CN 1,2-Propanedione, 1-[4-(nitrooxy)-1-piperidinyl]- (CA INDEX NAME)



RN 857464-12-1 CAPLUS
 CN Propanamide, N-[3-(nitrooxy)propyl]-2-oxo- (CA INDEX NAME)




RN 857464-13-2 CAPLUS
 CN Propanamide, N-[2,2-dimethyl-3-(nitrooxy)propyl]-2-oxo- (CA INDEX NAME)



RN 857464-14-3 CAPLUS
 CN Propanamide, N-[(1S)-2-(nitrooxy)-1-phenylethyl]-2-oxo- (CA INDEX NAME)


Absolute stereochemistry.




RN 857464-15-4 CAPLUS
 CN Propanamide, N-[(1S)-1-[(nitrooxy)methyl]-2-phenylethyl]-2-oxo- (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 cirrhosis, pre-eclampsia, osteoporosis, nephropathy, reperfusion injury following ischemia, and/or preserving tissues, organs, organ parts and/or limbs using these compns. The nitric oxide releasing group is preferably a nitro group, a nitroso group, and/or a heterocyclic nitric oxide donor group. The heterocyclic nitric oxide donor group is preferably a furazan, a sydnonimine, an oxatriazole-5-one and/or an oxatriazole-5-imine. Thus, a mixt. of nitrooxy-4-piperidinyl nitrate (1.045 g, 5 mmol) and pyruvic acid (440 mg, 5 mmol) in dichloromethane was treated with triethylamine (0.7 mL). To this soln. was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDAC) (960 mg, 5 mmol) followed by dimethylaminopyridine (DMAP, 610 mg, 5 mmol). The resulting soln. was then stirred under nitrogen atm. at room temp. overnight. The reaction mixt. was dild. with dichloromethane and washed with water, brine, dried over sodium sulfate, filtered, and the solvent was evapd. at reduced pressure. The product was purified by column chromatog. to give 1-[4-(nitrooxy)piperidinyl]propane-1,2-dione (470 mg, 44% yield) as a colorless thick oil.
 IT 857464-11-0P 857464-12-1P 857464-13-2P
 857464-14-3P 857464-15-4P 857464-18-7P
 857464-19-8P 857464-20-1P 857464-21-2P
 857464-22-3P 857464-23-4P 857464-24-5P
 857464-25-6P 857464-26-7P 857464-27-8P
 857464-29-0P 857464-30-3P 857464-31-4P
 857464-32-5P 857464-33-6P 857464-34-7P
 857464-35-8P 857464-36-9P 857464-37-0P
 857464-38-1P 857464-39-2P 857464-40-5P
 857464-41-6P 857464-42-7P 857464-43-8P
 857464-44-9P 857464-45-0P 857464-46-1P
 857464-47-2P 857464-48-3P 857464-49-4P
 857464-50-7P 857464-51-8P 857464-52-9P
 857464-53-0P 857464-54-1P 857464-55-2P
 857464-56-3P 857464-57-4P 857464-58-5P
 857464-59-6P 857464-60-9P 857464-61-0P
 857464-62-1P 857464-63-2P 857464-64-3P
 857464-65-4P 857464-66-5P 857464-67-6P
 857464-68-7P 857464-69-8P 857464-70-1P
 857464-71-2P 857464-72-3P 857464-73-4P
 857464-74-5P 857464-75-6P 857464-76-7P
 857464-77-8P 857464-78-9P 857464-79-0P
 857464-80-3P 857464-81-4P 857464-82-5P
 857464-83-6P 857464-84-7P 857464-85-8P
 857464-86-9P 857464-87-0P 857464-88-1P
 857464-89-2P 857464-90-5P 857464-91-6P
 857464-92-7P 857464-93-8P 857464-94-9P
 857464-95-0P 857464-96-1P 857464-97-2P
 857464-98-3P 857464-99-4P 857465-00-0P
 857465-01-1P 857465-02-2P 857465-03-3P
 857465-04-4P 857465-05-5P 857465-06-6P
 857465-07-7P 857465-08-8P 857465-09-9P
 857465-10-2P 857465-11-3P 857465-12-4P
 857465-13-5P 857465-14-6P 857465-15-7P
 857465-16-8P 857465-21-5P 857465-22-6P
 857465-23-7P 857465-24-8P 857465-25-9P




RN 857464-18-7 CAPLUS
 CN Propanoic acid, 2-oxo-, [3-[(nitrooxy)methyl]phenyl]methyl ester (CA INDEX NAME)



RN 857464-19-8 CAPLUS
 CN Propanoic acid, 2-oxo-, [4-(nitrooxy)-1-piperidinyl]methyl ester (CA INDEX NAME)




RN 857464-20-1 CAPLUS
 CN Propanoic acid, 2-oxo-, 2-[4-(nitrooxy)-1-piperidinyl]ethyl ester (CA INDEX NAME)




RN 857464-21-2 CAPLUS
 CN Propanoic acid, 2-oxo-, 3-[4-(nitrooxy)-1-piperidinyl]propyl ester (CA INDEX NAME)

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-22-3 CAPLUS
CN Propanoic acid, 2-oxo-, (2R)-2,3-bis(nitrooxy)propyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-23-4 CAPLUS
CN Propanoic acid, 2-oxo-, [4-[2-(nitrooxy)ethyl]phenyl]methyl ester (CA INDEX NAME)




RN 857464-24-5 CAPLUS
CN Propanoic acid, 2-oxo-, [4-[(nitrooxy)methyl]-1-piperazinyl]methyl ester (CA INDEX NAME)




RN 857464-25-6 CAPLUS
CN Propanoic acid, 2-oxo-, 2-[4-[(nitrooxy)methyl]-1-piperazinyl]ethyl ester (CA INDEX NAME)

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 857464-30-3 CAPLUS
CN Propanoic acid, 2-oxo-, 3-[4-[2-(nitrooxy)ethyl]-1-piperazinyl]propyl ester (CA INDEX NAME)




RN 857464-31-4 CAPLUS
CN Propanoic acid, 2-oxo-, [4-[3-(nitrooxy)propyl]-1-piperazinyl]methyl ester (CA INDEX NAME)



RN 857464-32-5 CAPLUS
CN Propanoic acid, 2-oxo-, 2-[4-[3-(nitrooxy)propyl]-1-piperazinyl]ethyl ester (CA INDEX NAME)




RN 857464-33-6 CAPLUS
CN Propanoic acid, 2-oxo-, 3-[4-[3-(nitrooxy)propyl]-1-piperazinyl]propyl ester (CA INDEX NAME)




RN 857464-34-7 CAPLUS
CN 1,2-Propanedione, 1-[2-[(nitrooxy)methyl]-1-piperidinyl]- (CA INDEX NAME)


L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-26-7 CAPLUS
CN Propanoic acid, 2-oxo-, 3-[4-[(nitrooxy)methyl]-1-piperazinyl]propyl ester (CA INDEX NAME)




RN 857464-27-8 CAPLUS
CN Propanoic acid, 2-oxo-, [4-[2-(nitrooxy)ethyl]-1-piperazinyl]methyl ester (CA INDEX NAME)




RN 857464-29-0 CAPLUS
CN Propanoic acid, 2-oxo-, 2-[4-[2-(nitrooxy)ethyl]-1-piperazinyl]ethyl ester (CA INDEX NAME)




L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 857464-35-8 CAPLUS
CN 1,2-Propanedione, 1-[3-[(nitrooxy)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 857464-36-9 CAPLUS
CN 1,2-Propanedione, 1-[4-[(nitrooxy)methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 857464-37-0 CAPLUS
CN L-Cysteine, S-[3-[[2-[2-(nitrooxy)ethoxy]ethyl]amino]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-38-1 CAPLUS
CN L-Cysteine, L-γ-glutamyl-S-[3-[[2-[2-(nitrooxy)ethoxy]ethyl]amino]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-39-2 CAPLUS
CN L-Cysteine, S-[3-[2-[4-[2-(nitrooxy)ethoxy]phenoxy]ethoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-40-5 CAPLUS
CN L-Cysteine, L-γ-glutamyl-S-[3-[2-[4-[2-(nitrooxy)ethoxy]phenoxy]ethoxy]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B




L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-45-0 CAPLUS
CN L-Cysteine, S-[3-[3-(nitrooxy)propyl]amino]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 857464-46-1 CAPLUS
CN Propanoic acid, 2-oxo-, 3-(nitrooxy)propyl ester (CA INDEX NAME)



RN 857464-47-2 CAPLUS
CN Propanoic acid, 2-oxo-, 2,2-dimethyl-3-(nitrooxy)propyl ester (CA INDEX NAME)



RN 857464-48-3 CAPLUS
CN Propanoic acid, 2-oxo-, 3-(nitrooxy)-2-[(nitrooxy)methyl]propyl ester (CA INDEX NAME)




RN 857464-49-4 CAPLUS

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 857464-41-6 CAPLUS
CN L-Cysteine, S-[3-[3-[(nitrooxy)methyl]phenyl]methoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-42-7 CAPLUS
CN L-Cysteine, L-γ-glutamyl-S-[3-[3-[(nitrooxy)methyl]phenyl]methoxy]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-43-8 CAPLUS
CN D-Cysteine, S-[3-[4-[(nitrooxy)methyl]phenyl]methoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 857464-44-9 CAPLUS
CN L-Cysteine, L-γ-glutamyl-S-[3-[4-[(nitrooxy)methyl]phenyl]methoxy]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN Propanoic acid, 2-oxo-, 2-(nitrooxy)-1-[(nitrooxy)methyl]ethyl ester (CA INDEX NAME)




RN 857464-50-7 CAPLUS
CN Propanamide, N-[1,3-bis(nitrooxy)propyl]-2-oxo- (CA INDEX NAME)



RN 857464-51-8 CAPLUS
CN Propanoic acid, 2-oxo-, [3,5-bis[(nitrooxy)methyl]phenyl]methyl ester (CA INDEX NAME)




RN 857464-52-9 CAPLUS
CN Propanoic acid, 2-oxo-, 2-methyl-3-(nitrooxy)-2-[(nitrooxy)methyl]propyl ester (CA INDEX NAME)




RN 857464-53-0 CAPLUS
CN Propanoic acid, 2-oxo-, 3-(nitrooxy)-2,2-bis[(nitrooxy)methyl]propyl ester (CA INDEX NAME)


L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-54-1 CAPLUS
CN Propanoic acid, 2-oxo-, 2-[4-[2-(nitrooxy)ethoxy]phenoxy]ethyl ester (CA INDEX NAME)



RN 857464-55-2 CAPLUS
CN Propanoic acid, 2-oxo-, 2-nitro-3-(nitrooxy)-2-[(nitrooxy)methyl]propyl ester (CA INDEX NAME)




RN 857464-56-3 CAPLUS
CN Propanamide, N-[2-[2-(nitrooxy)ethoxy]ethyl]-2-oxo- (CA INDEX NAME)




RN 857464-57-4 CAPLUS
CN Propanoic acid, 2-oxo-, [4-[(nitrooxy)methyl]phenyl]methyl ester (CA INDEX NAME)

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-58-5 CAPLUS
CN L-Glutamic acid, 5-[2-[(1,2-dioxopropyl)amino]-3-(nitrooxy)-2-[(nitrooxy)methyl]propyl] ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-59-6 CAPLUS
CN L-Glutamine, N-[2-(1,2-dioxopropoxy)-1,1-bis[(nitrooxy)methyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-60-9 CAPLUS
CN L-Glutamic acid, 5-[2-[(1,2-dioxopropoxy)methyl]-3-(nitrooxy)propyl] ester (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-61-0 CAPLUS
CN L-Glutamic acid, 5-[2-[(1,2-dioxopropoxy)methyl]-2-methyl-3-(nitrooxy)propyl] ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-62-1 CAPLUS
CN L-Glutamic acid, 5-[2-[(1,2-dioxopropoxy)-1,1-bis[(nitrooxy)methyl]ethyl] ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-63-2 CAPLUS
CN L-Glutamic acid, 5-[1-[(1,2-dioxopropoxy)methyl]-1-nitro-2-(nitrooxy)ethyl] ester (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-64-3 CAPLUS
CN L-Glutamic acid, 5-[1-[(1,2-dioxopropyl)amino]-2-(nitrooxy)ethyl] ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-65-4 CAPLUS
CN L-Glutamic acid, 5-[3-[(1,2-dioxopropoxy)methyl]-5-[(nitrooxy)methyl]phenyl]methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-66-5 CAPLUS
CN L-Glutamic acid, 5-[2-(1,2-dioxopropoxy)-3-(nitrooxy)propyl] ester (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-67-6 CAPLUS
 CN L-Glutamic acid, 5-[1-[(1,2-dioxopropoxy)methyl]-2-(nitrooxy)ethyl]
 ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-68-7 CAPLUS
 CN L-Glutamine, N-[1-[(1,2-dioxopropoxy)methyl]-2-(nitrooxy)ethyl]- (CA
 INDEX NAME)


Absolute stereochemistry.



RN 857464-69-8 CAPLUS
 CN L-Cysteine, L-gamma-glutamyl-S-[3-[(2-nitrooxy)propyl]amino]-2,3-
 dioxopropyl]-, 2-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-73-4 CAPLUS
 CN L-Cysteine, L-gamma-glutamyl-S-[3-[[2-(nitrooxy)-1-
 [(nitrooxy)methyl]ethyl]amino]-2,3-dioxopropyl]-, 2-methyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-74-5 CAPLUS
 CN L-Cysteine, S-[3-[3-(nitrooxy)-2,2-bis[(nitrooxy)methyl]propoxy]-2,3-
 dioxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-75-6 CAPLUS
 CN L-Cysteine, L-gamma-glutamyl-S-[3-[3-(nitrooxy)-2,2-
 bis[(nitrooxy)methyl]propoxy]-2,3-dioxopropyl]-, 2-methyl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-70-1 CAPLUS
 CN L-Cysteine,
 S-[3-[[2,2-dimethyl-3-(nitrooxy)propyl]amino]-2,3-dioxopropyl]-
 , methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-71-2 CAPLUS
 CN L-Cysteine, L-gamma-glutamyl-S-[3-[[2,2-dimethyl-3-
 (nitrooxy)propyl]amino]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 857464-72-3 CAPLUS
 CN L-Cysteine, S-[3-[[2-(nitrooxy)-1-[(nitrooxy)methyl]ethyl]amino]-2,3-
 dioxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-76-7 CAPLUS
 CN L-Cysteine, S-[3-[2-methyl-3-(nitrooxy)-2-[(nitrooxy)methyl]propoxy]-2,3-
 dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-77-8 CAPLUS
 CN L-Cysteine, L-gamma-glutamyl-S-[3-[2-methyl-3-(nitrooxy)-2-
 [(nitrooxy)methyl]propoxy]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 857464-78-9 CAPLUS
 CN L-Cysteine, S-[3-[2-nitro-3-(nitrooxy)-2-[(nitrooxy)methyl]propoxy]-2,3-
 dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 857464-79-0 CAPLUS
 CN L-Cysteine, L-γ-glutamyl-S-[3-[2-nitro-3-(nitrooxy)-2-
 [(nitrooxy)methyl]propoxy]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 857464-80-3 CAPLUS
 CN L-Cysteine, S-[3-[3-(nitrooxy)propoxy]-2,3-dioxopropyl]-, methyl ester
 (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-81-4 CAPLUS
 CN L-Cysteine, L-γ-glutamyl-S-[3-[3-(nitrooxy)propoxy]-2,3-dioxopropyl]-
 , 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-82-5 CAPLUS
 CN L-Cysteine, S-[3-[2,2-dimethyl-3-(nitrooxy)propoxy]-2,3-dioxopropyl]-,
 methyl ester (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 857464-86-9 CAPLUS
 CN L-Cysteine, S-[3-[2-(nitrooxy)-1-[(nitrooxy)methyl]ethoxy]-2,3-
 dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-87-0 CAPLUS
 CN L-Cysteine, L-γ-glutamyl-S-[3-[2-(nitrooxy)-1-
 [(nitrooxy)methyl]ethoxy]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 857464-88-1 CAPLUS
 CN L-Cysteine, S-[3-[3,5-bis[(nitrooxy)methyl]phenyl]methoxy]-2,3-
 dioxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-89-2 CAPLUS
 CN L-Cysteine, L-γ-glutamyl-S-[3-[3,5-bis[(nitrooxy)methyl]phenyl]meth
 oxy]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-83-6 CAPLUS
 CN L-Cysteine, L-γ-glutamyl-S-[3-[2,2-dimethyl-3-(nitrooxy)propoxy]-2,3-
 dioxopropyl]-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-84-7 CAPLUS
 CN L-Cysteine, S-[3-[3-(nitrooxy)-2-[(nitrooxy)methyl]propoxy]-2,3-
 dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-85-8 CAPLUS
 CN L-Cysteine, L-γ-glutamyl-S-[3-[3-(nitrooxy)-2-
 [(nitrooxy)methyl]propoxy]-2,3-dioxopropyl]-, 2-methyl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-90-5 CAPLUS
 CN L-Cysteine, N-acetyl-S-[3-[2-(nitrooxy)ethoxy]ethyl]amino]-2,3-
 dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 857464-91-6 CAPLUS
 CN L-Cysteine, N-acetyl-S-[3-[3-(nitrooxy)propyl]amino]-2,3-dioxopropyl]-,
 methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-92-7 CAPLUS
 CN L-Cysteine, N-acetyl-S-[3-[2-[4-[2-(nitrooxy)ethoxy]phenoxy]ethoxy]-2,3-
 dioxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-93-8 CAPLUS
 CN L-Cysteine, N-acetyl-S-[3-[2,2-dimethyl-3-(nitrooxy)propyl]amino]-2,3-


L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 857464-94-9 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[[3-[(nitrooxy)methyl]phenyl]methoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-95-0 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[[2-(nitrooxy)-1-[(nitrooxy)methyl]ethyl]amino]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-96-1 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[[4-[(nitrooxy)methyl]phenyl]methoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857465-00-0 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[[2-(nitrooxy)-1-[(nitrooxy)methyl]ethoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857465-01-1 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[[3-(nitrooxy)propoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857465-02-2 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[[3,5-bis[(nitrooxy)methyl]phenyl]methoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857464-97-2 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[[3-(nitrooxy)-2,2-bis[(nitrooxy)methyl]propoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857464-98-3 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[[2-methyl-3-(nitrooxy)-2-[(nitrooxy)methyl]propoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857464-99-4 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[[2-nitro-3-(nitrooxy)-2-[(nitrooxy)methyl]propoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857465-03-3 CAPLUS
CN L-Cysteine, N-acetyl-S-[3-[[2,2-dimethyl-3-(nitrooxy)propoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 857465-04-4 CAPLUS
CN L-Glutamic acid, 5-[(2S)-3-[(2R)-2,3-bis(nitrooxy)propoxy]-2-[(1,2-dioxopropyl)amino]-3-oxopropyl] ester (CA INDEX NAME)


Absolute stereochemistry.



RN 857465-05-5 CAPLUS
CN L-Glutamic acid, 5-[(2S)-3-[(2S)-2,3-bis(nitrooxy)propoxy]-2-[(1,2-dioxopropyl)amino]-3-oxopropyl] ester (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857465-06-6 CAPLUS
 CN L-Ornithine, N2-(1,2-dioxopropyl)-N5-L-γ-glutamyl-,
 2-[(2R)-2,3-bis(nitrooxy)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857465-07-7 CAPLUS
 CN L-Ornithine, N2-(1,2-dioxopropyl)-N5-L-γ-glutamyl-,
 2-[(2S)-2,3-bis(nitrooxy)propyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 857465-08-8 CAPLUS
 CN L-Lysine, N2-(1,2-dioxopropyl)-N6-L-γ-glutamyl-,
 2-[(2R)-2,3-bis(nitrooxy)propyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857465-12-4 CAPLUS
 CN L-Lysinamide, N-[(2R)-2,3-bis(nitrooxy)propyl]-N2-(1,2-dioxopropyl)-N6-L-
 γ-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857465-13-5 CAPLUS
 CN L-Lysinamide, N-[(2S)-2,3-bis(nitrooxy)propyl]-N2-(1,2-dioxopropyl)-N6-L-
 γ-glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 857465-14-6 CAPLUS
 CN L-Lysine, N2-(1,2-dioxopropyl)-N6-L-γ-glutamyl-,
 2-[3-(nitrooxy)-2,2-bis[(nitrooxy)methyl]propyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857465-09-9 CAPLUS
 CN L-Lysine, N2-(1,2-dioxopropyl)-N6-L-γ-glutamyl-,
 2-[(2S)-2,3-bis(nitrooxy)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857465-10-2 CAPLUS
 CN L-Norvaline, 5-[(2R)-3-[(2R)-2,3-bis(nitrooxy)propoxy]-2-[(1,2-
 dioxopropyl)amino]-3-oxopropyl]thio]-5-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 857465-11-3 CAPLUS
 CN L-Norvaline, 5-[(2S)-3-[(2R)-2,3-bis(nitrooxy)propoxy]-2-[(1,2-
 dioxopropyl)amino]-3-oxopropyl]thio]-5-oxo- (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857465-15-7 CAPLUS
 CN L-Lysine, N2-(1,2-dioxopropyl)-N6-L-γ-glutamyl-, 2-ester with
 3,6-anhydro-2-deoxy-β-L-glycero-hexofuranose 5-nitrate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857465-16-8 CAPLUS
 CN L-Lysine, N2-(1,2-dioxopropyl)-N6-L-γ-glutamyl-, 2-ester with
 3,6-anhydro-2-deoxy-β-D-glycero-hexofuranose 5-nitrate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 857465-21-5 CAPLUS
 CN L-Lysine, L-γ-glutamyl-N6-(1,2-dioxopropyl)-, 2-[(2R)-2,3-
 bis(nitrooxy)propyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 857465-22-6 CAPLUS
 CN L-Lysine, L-γ-glutamyl-N6-(1,2-dioxopropyl)-, 2-[(2S)-2,3-bis(nitrooxy)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857465-23-7 CAPLUS
 CN L-Lysinamide, L-γ-glutamyl-N-[(2R)-2,3-bis(nitrooxy)propyl]-N6-(1,2-dioxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-24-8 CAPLUS
 CN L-Lysinamide, L-γ-glutamyl-N-[(2S)-2,3-bis(nitrooxy)propyl]-N6-(1,2-dioxopropyl)- (9CI) (CA INDEX NAME)

L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 857465-27-1 CAPLUS
 CN L-Ornithine, L-γ-glutamyl-N5-(1,2-dioxopropyl)-, 2-[(2R)-2,3-bis(nitrooxy)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-28-2 CAPLUS
 CN L-Ornithine, L-γ-glutamyl-N5-(1,2-dioxopropyl)-, 2-[(2S)-2,3-bis(nitrooxy)propyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857465-29-3 CAPLUS
 CN L-Cysteine, N-acetyl-S-[3-[3-(nitrooxy)-2-[(nitrooxy)methyl]propoxy]-2,3-dioxopropyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 857465-25-9 CAPLUS
 CN L-Serine, L-γ-glutamyl-, 2-[(2R)-2,3-bis(nitrooxy)propyl] ester, 2-oxopropanoate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857465-26-0 CAPLUS
 CN L-Serine, L-γ-glutamyl-, 2-[(2S)-2,3-bis(nitrooxy)propyl] ester, 2-oxopropanoate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L12 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:585947 CAPLUS
 DOCUMENT NUMBER: 135:361671
 TITLE: New methodology for ozone depletion potentials of short-lived compounds: N-propyl bromide as an example
 AUTHOR(S): Wuebbles, Donald J.; Patten, Kenneth O.; Johnson, Matthew T.; Kotamarthi, Rao
 CORPORATE SOURCE: Department of Atmospheric Sciences, University of Illinois, Urbana, IL, USA
 SOURCE: Journal of Geophysical Research, [Atmospheres] (2001), 106 (D13), 14551-14571
 CODEN: JGRDE3; ISSN: 0148-0227
 PUBLISHER: American Geophysical Union
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A number of the compds. proposed as replacements for substances controlled under the Montreal Protocol have extremely short atmospheric lifetimes, on the order of days to a few months. An important example is Pr bromide (also referred to as 1-bromopropane, CH₂BrCH₂CH₃ or simplified as 1-C3H7Br or nPB). This compound, useful as a solvent, has an atmospheric lifetime of <20 days due to its reaction with hydroxyl radicals. Because nPB contains bromine, any amount reaching the stratosphere has the potential to affect concns. of stratospheric ozone. The definition of ozone depletion potentials (ODPs) needs to be modified for such short-lived compds. to account for the location and timing of emissions. It is not adequate to treat these chems. as if they were uniformly emitted at all latitudes and longitudes as is normally done for longer-lived gases. Thus, for short-lived compds., policymakers will need a table of ODP values instead of the single value generally provided in past studies. This study uses the MOZART2 3-dimensional chemical transport model in combination with studies with our less computationally expensive 2-dimensional model to examine the potential effects of nPB on stratospheric ozone. Multiple facets of this study examine key questions regarding the amount of bromine reaching the stratosphere following emission of nPB. Our most significant findings from this study for the purposes of short-lived replacement compound ozone effects are summarized as follows. The degradation of nPB produces a significant quantity of bromoacetone, which increases the amount of bromine transported to the stratosphere due to nPB. However, much of that effect is not due to bromoacetone itself, but instead to inorg. bromine which is produced from tropospheric oxidation of nPB, bromoacetone, and other degradation products and is transported above the dry and wet deposition processes of the model. The MOZART2 nPB results indicate a minimal correction of the 2-dimensional results in order to derive our final results: an nPB chemical lifetime of 19 days and an ODP range of 0.033 to 0.040 for assumed global emissions over landmasses, 19 days and 0.021 to 0.028, resp., for assumed emissions in the industrialized regions of the Northern Hemisphere, and 9 days and 0.087 to 0.105, resp., for assumed emission in tropical

L12 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 Asia.
 IT 340171-63-3 372952-10-8
 RL: GPR (Geological or astronomical process); POL (Pollutant); RCT (Reactant); OCCU (Occurrence); PROC (Process); RACT (Reactant or reagent) (formation from PrBr and calcn. of atmospheric half-life and rainout lifetime;
 new methodol. for calcn. of ozone depletion potentials of short-lived compds. such as Pr bromide)
 RN 340171-63-3 CAPLUS
 CN 2-Propanone, 3-bromo-1-(nitrodioxy)-1-oxo- (CA INDEX NAME)




RN 372952-10-8 CAPLUS
 CN Propanoyl bromide, 3-(nitrodioxy)-2,3-dioxo- (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L12 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:287681 CAPLUS
 DOCUMENT NUMBER: 134:370967
 TITLE: Effects of n-propyl bromide and other short lived chemicals on stratospheric ozone
 AUTHOR(S): Wuebbles, Donald J.; Patten, Kenneth O.; Johnson, Matthew T.
 CORPORATE SOURCE: University of Illinois, Urbana, IL, 61801, USA
 SOURCE: Symposium Atmospheric Chemistry Issues in the 21st Century, [Preprints], Long Beach, CA, United States, Jan. 9-14, 2000 (2000), 77-84. American Meteorological Society: Boston, Mass.
 CODEN: 69BES4
 DOCUMENT TYPE: Conference
 LANGUAGE: English
 AB This study uses the MOZART three-dimensional model in combination with studies with a less computationally expensive two-dimensional model to examine potential effects of Pr bromide (nPB) on stratospheric ozone. Multiple facets of this study examine key questions regarding the amount of bromine reaching the stratosphere following emission of nPB.
 IT 340171-63-3
 RL: FMU (Formation, unclassified); PEP (Physical, engineering or chemical process); POL (Pollutant); FORM (Formation, nonpreparative); OCCU (Occurrence); PROC (Process) (effects of Pr bromide and other short lived chems. on stratospheric ozone)
 RN 340171-63-3 CAPLUS
 CN 2-Propanone, 3-bromo-1-(nitrodioxy)-1-oxo- (CA INDEX NAME)




REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L12 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1992:531499 CAPLUS
 DOCUMENT NUMBER: 117:131499
 ORIGINAL REFERENCE NO.: 117:22851a,22854a
 TITLE: Preparation of hexitol derivatives as cardiovascular agents.
 INVENTOR(S): Suzuki, Fumio; Hayashi, Hiroaki; Kubo, Kazuhiro; Ikeda, Junichi
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo K. K., Japan
 SOURCE: Eur. Pat. Appl., 22 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 485723	A1	19920520	EP 1991-116548	19910927
EP 485723	B1	19940914		
R: DE, FR, GB, IT				
US 5120737	A	19920609	US 1991-764827	19910924
CA 2052082	A1	19920329	CA 1991-2052082	19910926
CA 2052082	C	19970527		
JP 04364184	A	19921216	JP 1991-247958	19910926
JP 3058955	B2	20000704		
PRIORITY APPLN. INFO.:			JP 1990-259385	A 19900928

OTHER SOURCE(S): MARPAT 117:131499
 GI



AB Title compds. I [R = H, (un)substituted alkylcycloalkyl, alkenyl, alkoxy, alkanoyl, piperidyn, X(CH2)mCYZ (CH2)n wherein m, n = 0-3, X, Y Z, = H, alkyl, alkoxy, alkanoyl, alkanoyloxy, HO, halo, O2N] or a salt thereof, useful as vasodilators, are prepared 5-Deoxy-5-(piperazin-1-yl)-1,4:3,6-dianhydro-L-iditol-2-nitrate (preparation given) in CH2Cl2 was stirred at 0° and reacted with Ac2O and pyridine to give after workup L-1 (R = Me) which was converted to the HCl salt (II). In a test for coronary vasospasm model in rats, II showed a min. effectiveness of <30 mg/kg,


p.o. Pharmaceutical formulations comprising I are given.

IT 143253-72-9P 143277-70-7P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as vasodilator)

RN 143253-72-9 CAPLUS
 CN L-Iditol,
 1,4:3,6-dianhydro-2-deoxy-2-[4-(1,2-dioxopropyl)-1-piperazinyl]-

L12 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 , 5-nitrate, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 143277-70-7 CAPLUS
 CN L-Iditol,
 1,4:3,6-dianhydro-2-deoxy-2-[4-(1,2-dioxopropyl)-1-piperazinyl]-
 , 5-nitrate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1976:121161 CAPLUS
DOCUMENT NUMBER: 84:121161
ORIGINAL REFERENCE NO.: 84:19665a,19668a
TITLE: 1,4-Disubstituted 2,3-butanediones
INVENTOR(S): Nikolaeva, A. D.; Kirsanov, A. P.
PATENT ASSIGNEE(S): Kazan Chemical-Technological Institute, USSR
SOURCE: U.S.S.R. From: Otkrytiya, Izobret., Prom. Obratzsy,
Tovarnye Znaki 1976, 53(8), 52.
CODEN: URXXAF
Patent

DOCUMENT TYPE: Russian
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
SU 504749	A1	19760228	SU 1974-2017453	19740419
PRIORITY APPLN. INFO.:			SU 1974-2017453	A 19740419

AB RCH2COCOCH2R (R = halo, alkoxy, ONO2) were prepared by N2O4 oxidation of
RCH2C=CCH2R in a refluxing halogenated hydrocarbon.
IT 58246-23-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 58246-23-4 CAPLUS
CN 2,3-Butanedione, 1,4-bis(nitrooxy)- (CA INDEX NAME)



L12 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1976:73584 CAPLUS
DOCUMENT NUMBER: 84:73584
ORIGINAL REFERENCE NO.: 84:12063a,12066a
TITLE: Synthesis of nitrates of some acetylene and
diacetylene alcohols
AUTHOR(S): Nikolaeva, A. D.; Kirsanov, A. P.; Kadyrova, R. G.
CORPORATE SOURCE: Kazan. Khim.-Tekhnol. Inst. im. Kirova, Kazan, USSR
SOURCE: Izvestiya Vysshikh Uchebnykh Zavedenii, Khimiya i
Khimicheskaya Tekhnologiya (1975), 18(11), 1715-16
CODEN: IVUKAR; ISSN: 0579-2991
Journal

DOCUMENT TYPE: Russian
LANGUAGE: Russian
AB Treating RC.tplbond.CCH2OX (I; R = H, Me, XCH2, XCH2C.tplbond.C; X = H)
and R1C.tplbond.CCHMeOX (II; R1 = H, XCHMeC.tplbond.C; X = H) with HNO3
in CH2Cl2 or Ac2O, or with N2O4 in CCl4 afforded the resp. I (X = NO2)
and
II (X = NO2) in $\leq 71.5\%$ yield.
IT 58246-23-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and borohydride reduction of)
RN 58246-23-4 CAPLUS
CN 2,3-Butanedione, 1,4-bis(nitrooxy)- (CA INDEX NAME)

